Union Budget 2022 | We were expecting some incentives for Pharma R&D: Kiran Mazumdar Shaw
The Hindu
Public investment was very low in this critical area of research and innovation, says Biocon chief
The industry was expecting some incentives for Pharma R&D in the budget as public investment was very low in this critical area of research and innovation, said Kiran Mazumdar Shaw, Chairperson, Biocon & Biocon Biologics.
“We were expecting some incentives for Pharma R&D in the Budget as public investment is very low in this critical area of research and innovation, which are key for spurring exponential economic growth,’‘ she reacted.
The finance minister has assured the government’s support for R&D expenditure in sunrise areas such as drones, AI, genomics, space and clean energy etc, she said adding, “We will need to see the fine print if there is anything on pharma.’‘
Adani Group plans a ₹1.5 lakh crore investment in Kutch, focusing on renewable energy, ports, and logistics over five years.
Mukesh Ambani announces ₹7 lakh crore investment in Gujarat, emphasizing clean energy, AI, and support for Olympic ambitions.
India mandates selfies and 'penny drop' for crypto KYC, discouraging ICOs and ensuring strict anti-money laundering measures.
Mukesh Ambani announces ₹7 lakh crore investment in Gujarat, emphasizing clean energy, AI, and support for Olympic ambitions.
The All India Cashew Association calls for urgent action against illegal cashew imports threatening India's domestic processing industry.
Moody’s upgrades Shriram Finance’s outlook to positive, citing strategic benefits from MUFG Bank's upcoming investment and improved financial stability.
India's rice exports soar to near record levels in 2025, driven by lifted curbs and increased global demand.
Dr. Reddy's responds to U.S. FDA queries regarding its Hyderabad biologics facility following a recent inspection.
Techno Paints plans a ₹500 crore IPO in FY27, featuring Sachin Tendulkar as brand ambassador to boost growth.
India's shift from Russian oil imports will have limited fiscal impact due to low global prices and reduced discounts.
The latest Household Consumption Expenditure Survey (HCES) by MoS&PI reveals a transformative shift in India’s economic landscape. For the first time in over a decade, granular data on Monthly Per Capita Expenditure (MPCE) highlights a significant decline in the proportional share of food spending—a classic validation of Engel’s Law as real incomes rise. Between 1999 and 2024, both rural and urban consumption pivoted away from staple-heavy diets toward protein-rich foods, health, education, and conveyance. As Indian households move beyond subsistence, these shifting Indian household spending patterns offer vital insights for social sector policy, poverty estimation, and the lived realities of an expanding middle-income population.
Investors shifted to Gold ETFs in December 2025, with record inflows amid macro uncertainty and declining equity returns.
Aurobindo Pharma's subsidiary receives Health Canada NOC for Dyrupeg, confirming its pegylated filgrastim biosimilar's safety and efficacy.